Clinical trials: Post Tuberculosis
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Tuberculosis
Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342
The purpose of this study is to assess the safety and immunogenicity of two doses of the TB vaccine administered according to a 0, 1 month schedule.
- Trial name
- NCT01669096
- Testing
- GSK Biologicals' investigational TB vaccine GSK 692342
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tuberculosis Infection, Tuberculosis Prevention
Qualitative Understanding of Community TB Services Pre and Post the CHIP-TB Trial
This qualitative study is designed to elicit the perspectives of relevant stakeholders to adapt a community-based TB/HIV intervention aimed on providing home-based TB prevention treatment (TPT) initiation for child TB contacts…
- Trial name
- NCT04494516
- Where
- 2 sites in Ethiopia, South Africa
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Pulmonary Tuberculosis
Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion
The purpose of this study is to evaluate the safety and immunogenicity of ID93 + GLA-SE vaccine when administered to adult pulmonary Tuberculosis (TB) patients, following successful completion of TB treatment with confirmed…
- Trial name
- NCT02465216
- Testing
- ID93 + GLA-SE
- Where
- 3 sites in South Africa
- Volunteers
- 60 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Post-tuberculosis Lung Disease, Tuberculosis (TB)
Pulmonary Rehabilitation Program in Patients With Post-Tuberculosis Lung Disease
Post-tuberculosis lung disease (PTLD) refers to persistent respiratory symptoms, functional limitation, and/or structural or physiological abnormalities after completion of anti-tuberculosis treatment.
- Trial name
- NCT07709507
- Testing
- Individualized Pulmonary Rehabilitation Program, Standard Post-Tuberculosis Care
- Volunteers
- 80 people
- Sponsor
- Filantropia Hospital
Non-tuberculous Mycobacterial Diseases, Tuberculosis
Safety And Efficacy Of Rifabutin In HIV Patients
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Conditions
- Non-tuberculous Mycobacterial Diseases, Tuberculosis, Inhibition of Disseminated Mycobacterium Avium Complex Disease Associated With HIV Infections
- Trial name
- NCT00810446
- Testing
- rifabutin
- Volunteers
- 72 people
- Sponsor
- Pfizer
Pulmonary Tuberculosis
Rehabilitation of People With Post-tuberculosis Lung Disease
Tuberculosis (TB) can leave numerous sequelae, where survivors experience a transition from an acute illness to living with a multifaceted chronic illness.
- Trial name
- NCT06127641
- Testing
- Standard care plus pulmonary rehabilitation, Standard Care
- Where
- 2 sites in Brazil
- Volunteers
- 40 people
- Sponsor
- Centro Universitário Augusto Motta
Bursa; Tuberculous, Hip Bursitis
Trochanteric Bursal Repair After a Total Hip Replacement - Are There Benefits During the First 90 Days
During total hip arthroplasty surgery, the trochanteric bursa is routinely excised. This anatomical structure, which functions as a soft tissue barrier, is generally recommended for removal as it facilitates the surgical…
- Conditions
- Bursa; Tuberculous, Hip Bursitis, Deep Gluteal Syndrome, Hip Disease
- Trial name
- NCT06553508
- Testing
- Trochanteric bursa repaired, Trochanteric bursa unrepaired
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Ankara City Hospital Bilkent
TB
Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients
Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB (MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely.
- Trial name
- NCT01055145
- Testing
- levofloxacin, moxifloxacin
- Where
- 29 sites in South Korea
- Volunteers
- 182 people
- Sponsor
- Seoul National University Hospital
Tuberculosis
Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US
The objective of this protocol is to obtain biological samples through leukapheresis and cryopreservation of cells for the future study, by in vitro assay, of immune responses after one dose of BCG in BCG-naïve healthy adults.
- Trial name
- NCT02413502
- Testing
- BCG
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Aeras
Tuberculosis
Evaluation of Tuberculosis Treatment Outcomes
Tuberculosis (TB) is an infectious disease caused by Mycobacterium species grouped in the Mycobacterium tuberculosis complex. TB remains a major global health problem, despite the fact that there are drugs that can eradicate the…
- Trial name
- CLIO-TB (NCT06942975)
- Testing
- Patients with turberculosis
- Where
- Italy
- Volunteers
- 111 people
- Sponsor
- Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
TB - Tuberculosis, TB
Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
Individual-level, unblinded randomized controlled trial of an 8-week (short arm) or 24-week (extended arm) pulmonary rehabilitation program, relative to standard of care, to prevent post-tuberculosis respiratory morbidity.
- Conditions
- TB - Tuberculosis, TB, TB Infection
- Trial name
- TB Pure (NCT07164742)
- Testing
- 8 week (short arm) Intervention - pulmonary rehabilitation, 24 week (long arm) Intervention - pulmonary rehabilitation
- Where
- 2 sites in India
- Volunteers
- 690 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant
Shortening Treatment by Advancing Novel Drugs
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of moxifloxacin, PA-824, and pyrazinamide treatments with varying doses and treatment lengths from 4 to 6 months in subjects with…
- Trial name
- STAND (NCT02342886)
- Testing
- Moxifloxacin, PA-824, Pyrazinamide
- Where
- 26 sites in Georgia, Kenya and 6 more
- Volunteers
- 284 people
- Sponsor
- Global Alliance for TB Drug Development
COVID-19, Tuberculosis
Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection
This study has two main objectives. First, the clinical characteristics and outcomes of hospitalized patients with symptomatic Covid-19 disease will be compared between persons with a history of past or current TB infection or…
- Conditions
- COVID-19, Tuberculosis, Post-acute COVID-19 Syndrome
- Trial name
- Co-TB (NCT05643781)
- Where
- South Africa
- Volunteers
- 157 people
- Sponsor
- The Aurum Institute NPC
HIV Infections, Tuberculosis
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 week, randomized, open-label, two arm study to compare the efficacy, safety and tolerability of HAART containing nevirapine 400 mg/day versus nevirapine 600 mg/day in HIV-1 infected patients started at 2-6 weeks after…
- Trial name
- NCT00476853
- Testing
- HAART containing nevirapine
- Where
- 6 sites in Thailand
- Volunteers
- 42 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Tuberculosis in Children, Chronic Lung Disease
Paediatric Post-TB Pulmonary Rehab Study
The goal of this clinical trial is to learn if a home-based pulmonary rehabilitation program is feasible and acceptable for children ages 6-15 who have recently completed treatment for pulmonary tuberculosis.
- Conditions
- Tuberculosis in Children, Chronic Lung Disease, Post Tuberculosis
- Trial name
- PPT Rehab (NCT07097961)
- Testing
- Pulmonary Rehabilitation
- Where
- Uganda
- Volunteers
- 40 people
- Sponsor
- University of Iowa
Kidney Transplant Infection, Tuberculosis
The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation
Organ transplant recipients are a high incidence group of tuberculosis infection, and the incidence rate is 7-27 times that of the general population.
- Conditions
- Kidney Transplant Infection, Tuberculosis, Isoniazid Toxicity
- Trial name
- PTTKT (NCT05249699)
- Testing
- Isoniazid, without any additional anti-tuberculosis treatment
- Volunteers
- 303 people
- Sponsor
- West China Hospital
Tuberculosis
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days.
- Trial name
- NCT00990990
- Testing
- PNU-100480, Linezolid
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.
Latent Tuberculosis, Staphylococcus Aureus
Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus…
- Trial name
- NCT05073926
- Testing
- No intervention is part of the study protocol
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Region Skane
Tuberculosis
The Time of Positive Conversion of Interferon-γ Releasing Assay After Tuberculosis Exposure
The aim is to evaluate the time of positive conversion after exposure to smear positive pulmonary tuberculosis (TB) in a platoon of Korean military, a closed communal setting.
- Trial name
- NCT00981071
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Armed Forces Capital Hospital, Republic of Korea